Sep 3Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Aug 6Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Aug 1Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Jul 30Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
May 9Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Apr 11Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Mar 18Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Feb 1Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Jan 24Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humans
Nov 27, 2023Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
Sep 12, 2023Anavex Announces Appointment of Dr Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
